Healthcare / Medical Instruments & SuppliesShanghai
$17.00
-0.56 (-3.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-124.7M · quality 57.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.9B
P/E
130.8x
↑EV/EBITDA
35.4x
↑ROE
1.0%
↑Gross Margin
24.9%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.4%
FCF CAGR
—
FCF margin
0.9%
FCF / Net income
0.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $628.3M · net income $42.8M · FCF $5.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $628.3M | $628.3M | $611.3M | $572.8M | $585.7M |
| Net Income | $42.8M | $42.8M | $22.5M | $7.9M | $68.1M |
| EBITDA | $100.1M | $100.1M | $78.1M | $61.4M | $117.7M |
| EPS | 0.12 | 0.12 | 0.07 | 0.02 | 0.20 |
| Gross Margin | 24.9% | 24.9% | 16.3% | 14.5% | 23.1% |
| Operating Margin | 1.8% | 1.8% | -7.1% | -7.3% | -1.6% |
| Net Margin | 6.8% | 6.8% | 3.7% | 1.4% | 11.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Current Ratio | 14.89 | 14.89 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $5.6M | $5.6M | $-182.0M | $-124.7M | $-224.8M |
| Returns | |||||
| ROE | 1.0% | 1.0% | 0.5% | 0.2% | 1.6% |
| Valuation | |||||
| P/E | 130.77 | 130.77 | 211.14 | 932.50 | 96.70 |
| EV/EBITDA | 35.39 | 35.39 | 37.20 | 81.22 | 34.30 |
| P/B | 1.43 | 1.43 | 1.13 | 1.77 | 1.57 |
| Growth & Yield | |||||
| Revenue Growth | 2.8% | 2.8% | 6.7% | -2.2% | — |
| EPS Growth | 71.4% | 71.4% | 250.0% | -90.0% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
132.5%
EPS terminal req.
$1.51
Spread vs growth
-61.1%
5Y implied EPS CAGR
72.4%
EPS terminal req.
$1.83
Spread vs growth
-0.9%
10Y implied EPS CAGR
37.7%
EPS terminal req.
$2.94
Spread vs growth
33.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.8%
Start / end P/E
256.0x → 141.7x
EPS bridge
0.07 → 0.12
Residual
-31.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.